Compare Cytokinetics Inc (CYTK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs TransMedics Group Inc — how do they compare? Cytokinetics Inc trades at $62.9 (market cap $8.62B), while TransMedics Group Inc trades at $77.43 (market cap $2.74B). The key difference: Cytokinetics Inc is far larger — about 3.1× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and TransMedics Group Inc for 24 Days on average.
| CYTK | TMDX | |
|---|---|---|
Market Cap | $8.62B | $2.74B |
Volume | 2,594,626 | 949,331 |
Sector | Health | Health |
52-Week High | $87.26 | $150.42 |
52-Week Low | $54.76 | $61.99 |
Typical Hold Time | 19 Days | 24 Days |
Enterprise Value | $8.72B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
